Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    YQ23
Previous Study | Return to List | Next Study

First-In-Man, Healthy Volunteer Study to Evaluate Safety on the Use of YQ23

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03802292
Recruitment Status : Recruiting
First Posted : January 14, 2019
Last Update Posted : January 18, 2019
Sponsor:
Information provided by (Responsible Party):
New B Innovation Limited

Brief Summary:
This study is to test the safety, tolerability, pharmacokinetics (PK-the amount of study drug in the blood), and immunogenicity (how the study drug affects the immune system) of single dose and dose levels of an investigational drug called YQ23.

Condition or disease Intervention/treatment Phase
Healthy Volunteers Biological: YQ23 Biological: Matching Placebo Phase 1

Detailed Description:

This is a first-in-man, phase 1, single-blind, randomized, placebo-controlled study in healthy volunteers. It will be conducted at a single centre and will enroll approximately 40 subjects. Subjects will either receive a single dose of study drug or placebo in a 3:1 ratio. Five dose levels of YQ23 will be evaluated.

Each dose level group will be divided into 2 cohorts, with each cohort being dosed at last 24 hours apart. The leading cohort will comprise of 2 subjects, with 1 subject receiving YQ23 and 1 subject receiving placebo. The remaining cohort will comprise of 6 subjects, with 5 receiving YQ23 and 1 receiving placebo.

Safety assessments will be performed throughout the dosing and follow-up periods, and multiple PK samples will be collected.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 40 participants
Allocation: Randomized
Intervention Model: Sequential Assignment
Intervention Model Description: Dose escalation study to determine the safe dose level.
Masking: Single (Participant)
Masking Description: Single blind, placebo-controlled
Primary Purpose: Other
Official Title: First-In-Man, Phase I, Single-Blind, Placebo-Controlled, Ascending Single Dose Study of Intravenous YQ23 in Healthy Male and Female Subjects to Assess Safety, Tolerability, and Pharmacokinetics
Actual Study Start Date : January 16, 2019
Estimated Primary Completion Date : May 21, 2019
Estimated Study Completion Date : June 10, 2019

Arm Intervention/treatment
Active Comparator: Single Ascending Dose YQ23 Biological: YQ23
Single dose of YQ23 delivered via intravenous route. Ascending dose levels will be evaluated

Placebo Comparator: Single Dose Placebo Biological: Matching Placebo
Single dose of the matching placebo delivered via intravenous route.




Primary Outcome Measures :
  1. Safety as assessed by the incidence of Treatment-emergent Adverse Events (TEAE) [ Time Frame: From the time of signing the Informed Consent Form to final discharge from the study (approximately 8 weeks) ]
    Number of TEAEs will be listed according to the severity (mild, moderate, severe) as assessed by the Investigator.

  2. Safety as assessed by the incidence of laboratory abnormalities, based on haematology, clinical chemistry, and urinalysis test results [ Time Frame: From the time of signing the Informed Consent Form to D8 visit (approximately 36 days) ]
    All serum biochemistry, haematology, and urinalysis data outside the clinical reference ranges will be listed by parameter and treatment.

  3. Safety as assessed by 12-lead electrocardiogram (ECG) [ Time Frame: From the time of signing the Informed Consent Form to D8 visit (approximately 36 days) ]
    ECG parameters such as PR, QRS, QT and QTcF in milliseconds will be recorded. Clinically significant abdominal findings will be reported as Adverse Events (AE).

  4. Safety as assessed by echocardiogram [ Time Frame: From the time of signing the Informed Consent Form to D2 visit (approximately 30 days) ]
    Clinically significant abnormal echocardiogram findings will be recorded as AEs.

  5. Safety as assessed by vital sign measurement of blood pressure [ Time Frame: From From the time of signing the Informed Consent Form to D8 visit (approximately 36 days) ]
    Systolic and Diastolic blood pressure (in mmHg) which is outside the clinical reference ranges and considered as clinically significant will be reported as AE.

  6. Safety as assessed by vital sign measurement of pulse rate [ Time Frame: From From the time of signing the Informed Consent Form to D8 visit (approximately 36 days) ]
    Pulse rate (in beats/min) which is outside the clinical reference ranges and considered as clinically significant will be reported as AE.

  7. Safety as assessed by vital sign measurement of oral body temperature [ Time Frame: From From the time of signing the Informed Consent Form to D8 visit (approximately 36 days) ]
    Body temperature (in degree Celsius) which is outside the clinical reference ranges and considered as clinically significant will be reported as AE.

  8. Safety as assessed by local tolerability assessment: pain [ Time Frame: From the time before dosing to D3 post dose (3 days) ]
    The intravenous (IV) infusion site will be assessed for pain according to the following scale [Grade 0=none, 1=does not interfere with activity, 2=interferes with activity or requires repeated use of non-narcotic pain medication, 3=prevent daily activity or requires repeated use of narcotic pain medication, 4=requires medical intervention greater than analgesia]. Grade 3 or above will be recorded as AE.

  9. Safety as assessed by local tolerability assessment: edema [ Time Frame: From the time before dosing to D3 post dose (3 days) ]
    The intravenous (IV) infusion site will be assessed for edema according to the following scale [Grade 0=0 to 24mm, 1=25 to 50mm and not interfere with activity, 2=51 to 100mm, or interferes with activity, 3=more than 100mm, and interferes with daily activity, 4=necrosis]. Grade 3 or above will be recorded as AE.

  10. Safety as assessed by local tolerability assessment: erythema intensity [ Time Frame: From the time before dosing to D3 post dose (3 days) ]
    The intravenous (IV) infusion site will be assessed for erythema intensity according to the following scale [Grade 0=None, 1=light pink, 2=pinkish red, 3=intense red]. Grade 3 or above will be recorded as AE.

  11. Safety as assessed by local tolerability assessment: erythema size [ Time Frame: From the time before dosing to D3 post dose (3 days) ]
    The intravenous (IV) infusion site will be assessed for erythema size according to the following scale [Grade 0=0 to 24mm, 1=25 to 50mm, 2=51 to 100mm, 3=more than 100mm, 4=necrosis or exfoliative dermatitis]. Grade 3 or above will be recorded as AE.


Secondary Outcome Measures :
  1. Pharmacokinetics of YQ23 as assessed by Area under curve (AUC) on all subjects [ Time Frame: From study Day 1 (dosing of study drug) until Day 4 of trial participation. ]
    Plasma levels of YQ23 will be serially evaluated following dosing of study drug, and the AUC will be calculated.

  2. Pharmacokinetics of YQ23 as assessed by the maximum concentration of YQ23 on all subjects [ Time Frame: From study Day 1 (dosing of study drug) until Day 4 of trial participation. ]
    Plasma levels of YQ23 will be serially evaluated following dosing of study drug, and the maximum plasma concentration (Cmax) will be calculated.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 50 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Males or females, of any ethnic origin, between 18 and 50 years of age, inclusive.
  • Body mass index between 18.0 and 30.0 kg/m2, inclusive, and body weight between 50 and 100 kg, inclusive.
  • In good health, determined by no clinically significant findings from medical history, physical examination, 12 lead ECG, vital sign measurements, and clinical laboratory evaluations (congenital non-hemolytic hyperbilirubinemia [eg, suspicion of Gilbert's syndrome based on total and direct bilirubin] is not acceptable) at Screening and Check in, as assessed by the Investigator (or designee).
  • Females of non-childbearing potential defined as permanently sterile (ie, due to hysterectomy, bilateral salpingectomy, or bilateral oophorectomy) or postmenopausal (defined as at least 12 months postcessation of menses without an alternative medical cause and follicle stimulating hormone level ≥ 40 mIU/mL). Females will not be pregnant or lactating, and females of childbearing potential and males will agree to use contraception as detailed in the protocol.
  • Able to comprehend and willing to sign an Informed Consent Form and to abide by the study restrictions.
  • Subjects must agree to receive a bovine product.

Exclusion Criteria:

  • Significant history or clinical manifestation of any metabolic, allergic, dermatological, hepatic, renal, haematological, pulmonary, cardiovascular, gastrointestinal, neurological, respiratory, endocrine, or psychiatric disorder, as determined by the Investigator (or designee).
  • History of significant hypersensitivity, intolerance, or allergy to any drug compound, food, or other substance (excluding non-active hay fever), unless approved by the Investigator (or designee).
  • Any abnormality in the 12-lead ECG that, in the opinion of the Investigator (or designee), increases the risk of participating in the study.
  • Any clinically relevant findings on echocardiography, including left ventricular ejection fraction < 50% at baseline.
  • Supine blood pressure and supine pulse rate higher than 140/90 mmHg and 100 bpm, respectively, or lower than 90/50 mmHg and 40 bpm, respectively, at Screening or Check-in, confirmed by a repeat measurement.
  • Liver function test results for aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), and/or bilirubin > 1.5 x Upper Limit of Normal (ULN) at Screening or Check-in confirmed by repeat measurement.
  • Total red blood cell count, total white blood cell count, and/or haemoglobin levels outside of the normal reference range at Screening or Check-in, confirmed by repeat measurement.
  • History of alcoholism or drug/chemical abuse within 2 years prior to Check in.
  • Alcohol consumption of > 21 units per week for males and > 14 units for females.
  • Positive alcohol breath test result or positive urine drug screen (confirmed by repeat) at Screening or Check in.
  • Positive hepatitis panel and/or positive human immunodeficiency virus test.
  • Participation in a clinical study involving administration of an investigational drug (new chemical entity) in the past 90 days prior to dosing.
  • Use or intend to use any prescription medications/products other than hormone replacement therapy (HRT), oral, implantable, transdermal, injectable, or intrauterine contraceptives within 14 days prior to dosing, unless deemed acceptable by the Investigator (or designee).
  • Use or intend to use slow release medications/products considered to still be active within 14 days prior to dosing, unless deemed acceptable by the Investigator (or designee).
  • Use or intend to use any non-prescription medications/products (with the exception of vitamins/mineral supplements) and phytotherapeutic/herbal/plant derived preparations within 7 days prior to dosing, unless deemed acceptable by the Investigator (or designee).
  • Smoke more than 10 cigarettes or use the equivalent tobacco or nicotine containing products per day.
  • Receipt of blood products within 2 months prior to Check in.
  • Receipt of bovine Haemoglobin-based Oxygen Carrier (HBOC) or other HBOC in the past.
  • Donation of blood from 3 months prior to Screening, plasma from 7 days prior to Screening, or platelets from 6 weeks prior to Screening, or donations on more than 2 occasions within the 12 months preceding dosing.
  • Poor peripheral venous access.
  • Have previously completed or withdrawn from this study.
  • Have known allergies to bovine products.
  • Are vegetarians.
  • Subjects who have had a clinically significant illness as determined by the Investigator within 4 weeks of the start of dose administration.
  • Subjects who, in the opinion of the Investigator (or designee), should not participate in this study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03802292


Contacts
Layout table for location contacts
Contact: Eric Nam +852 2133 5332 eric.nam@newbinnovation.com
Contact: Yolanda Yan +852 2133 6054 yolanda.yan@newbinnovation.com

Locations
Layout table for location information
United Kingdom
Covance CRU Limited Recruiting
Leeds, United Kingdom
Contact    +44 0113 301 3500      
Principal Investigator: Jim Bush, Dr.         
Sponsors and Collaborators
New B Innovation Limited
Investigators
Layout table for investigator information
Study Director: Billy Lau, PhD New B Innovation Limited

Layout table for additonal information
Responsible Party: New B Innovation Limited
ClinicalTrials.gov Identifier: NCT03802292     History of Changes
Other Study ID Numbers: NBI(CT)-YQ23-2015-001
First Posted: January 14, 2019    Key Record Dates
Last Update Posted: January 18, 2019
Last Verified: January 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No